US 12,391,675 B2
NLRP3 modulators
Ashvinikumar V. Gavai, Princeton Junction, NJ (US); Derek J. Norris, Pennington, NJ (US); Daniel O'Malley, New Hope, PA (US); Steven P. Seitz, Swarthmore, PA (US); Jay A. Markwalder, Lahaska, PA (US); David K. Williams, Delran, NJ (US); Hua Gong, King of Prussia, PA (US); Scott Hunter Watterson, Pennington, NJ (US); and Christine M. Tarby, Lawrenceville, NJ (US)
Assigned to Innate Tumor Immunity, Inc., Princeton, NJ (US)
Appl. No. 17/422,512
Filed by INNATE TUMOR IMMUNITY, INC., Princeton, NJ (US)
PCT Filed Jan. 13, 2020, PCT No. PCT/US2020/013264
§ 371(c)(1), (2) Date Jul. 13, 2021,
PCT Pub. No. WO2020/150115, PCT Pub. Date Jul. 23, 2020.
Claims priority of provisional application 62/791,979, filed on Jan. 14, 2019.
Prior Publication US 2022/0089572 A1, Mar. 24, 2022
Int. Cl. C07D 403/04 (2006.01); A61P 35/00 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 487/10 (2006.01); C07D 491/08 (2006.01); C07D 493/08 (2006.01); C07D 493/10 (2006.01); C07D 498/08 (2006.01)
CPC C07D 403/04 (2013.01) [A61P 35/00 (2018.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 487/10 (2013.01); C07D 491/08 (2013.01); C07D 493/08 (2013.01); C07D 493/10 (2013.01); C07D 498/08 (2013.01)] 13 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
W is independently selected from: —NH—R6, —NH—CH2—R6,

OG Complex Work Unit Chemistry
and
R6 is independently selected from

OG Complex Work Unit Chemistry
X2 is independently N or CH; and
R7 is independently a heteroaryl including 5 ring atoms, wherein from 1 to 4 ring atoms are each independently selected from N, NH, N(C1-4 alkyl), O, and S.